NewsMV
Biotech deal volume has climbed to a record, driven by fear of missing out among major pharmaceutical companies as the prospect of key drug patents expiring concentrates minds.
The urgency is structural: when exclusivity on lucrative branded medicines runs out, generic competition moves in fast, and the search for the next blockbuster replacement is now pushing dealmaking to levels the sector has not seen before.
The patent cliff in focus Drug patents do not last indefinitely, and for large pharmaceutical companies whose revenue depends on a handful of high-earning products, the expiration timeline is not an abstraction.
Those dates are filed and public. Every major drugmaker knows when the clock runs out on its key assets.
Keep reading